These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 31910903)
1. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Parker WAE; Schulte C; Barwari T; Phoenix F; Pearson SM; Mayr M; Grant PJ; Storey RF; Ajjan RA Cardiovasc Diabetol; 2020 Jan; 19(1):3. PubMed ID: 31910903 [TBL] [Abstract][Full Text] [Related]
2. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G; Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041 [TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. Parker WAE; Sagar R; Kurdee Z; Hawkins F; Naseem KM; Grant PJ; Storey RF; Ajjan RA Cardiovasc Diabetol; 2021 Dec; 20(1):238. PubMed ID: 34920734 [TBL] [Abstract][Full Text] [Related]
6. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Angiolillo DJ; Badimon JJ; Saucedo JF; Frelinger AL; Michelson AD; Jakubowski JA; Zhu B; Ojeh CK; Baker BA; Effron MB Eur Heart J; 2011 Apr; 32(7):838-46. PubMed ID: 21252171 [TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850 [TBL] [Abstract][Full Text] [Related]
8. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Serebruany VL; Malinin AI; Pokov AN; Hanley DF Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263 [TBL] [Abstract][Full Text] [Related]
9. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A Platelets; 2015; 26(6):593-7. PubMed ID: 25350775 [TBL] [Abstract][Full Text] [Related]
11. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. Franchi F; Rollini F; Cho JR; King R; Phoenix F; Bhatti M; DeGroat C; Tello-Montoliu A; Zenni MM; Guzman LA; Bass TA; Ajjan RA; Angiolillo DJ Thromb Haemost; 2016 Mar; 115(3):622-31. PubMed ID: 26633836 [TBL] [Abstract][Full Text] [Related]
12. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644 [TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial. Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311 [TBL] [Abstract][Full Text] [Related]
15. Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. Tsukiyama Y; Kozuki A; Shinke T; Otake H; Kijima Y; Masano T; Nagoshi R; Shibata H; Takeshige R; Yanaka KI; Shite J; Hirata KI J Cardiol; 2018 Nov; 72(5):403-410. PubMed ID: 29731189 [TBL] [Abstract][Full Text] [Related]
16. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221 [TBL] [Abstract][Full Text] [Related]
17. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770 [TBL] [Abstract][Full Text] [Related]
18. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703 [TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. Rollini F; Franchi F; Cho JR; Degroat C; Bhatti M; Ferrante E; Patel R; Darlington A; Tello-Montoliu A; Desai B; Ferreiro J; Muniz-Lozano A; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ J Cardiovasc Transl Res; 2014 Feb; 7(1):53-63. PubMed ID: 24395495 [TBL] [Abstract][Full Text] [Related]